Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

作者：Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Daniel Morillo, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Raúl Córdoba, Toshihiko Oki, Monica Wielgos-Bonvallet, Mina Khoshdeli, Yi Hao, Jennifer Marek, Malene Risum, David Belada · 发表于：Blood · 年份：2025 · DOI：10.1182/blood-2025-1955 · 被引用次数：3 · 研究领域：Lymphoma Diagnosis and Treatment、CAR-T cell therapy research、Chronic Lymphocytic Leukemia Research

Abstract Introduction: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard of care (SOC) for patients with untreated (1L) diffuse large B-cell lymphoma (DLBCL). While R-CHOP is considered curative, approximately one-third of patients relapse, typically within the first 2 years after an initial response. Patients with International Prognostic Index (IPI) scores ≥3 have poorer outcomes, with complete response (CR) rates of ~50% and 5-year PFS rates of ~46%–58% (Ruppert AS, et al. Blood 2020;135:2041–2048). Epcoritamab, a CD3×CD20 bispecific antibody, has demonstrated high response rates as monotherapy or in combination with SOC for patients with 1L DLBCL, regardless of age and fitness. Here, we report efficacy and safety from a 3-year follow-up of patients who received epcoritamab + R-CHOP in the EPCORE® NHL-2 trial (NCT04663347). Methods: Patients with 1L CD20+ DLBCL and IPI score 3–5 received subcutaneous epcoritamab (0.16 mg on cycle 1 [C1] day 1 [D1], 0.8 mg on C1D8, and 48 mg thereafter; QW in C1–4; Q3W in C5–6) + R-CHOP for 6 Cs (21 days each), followed by epcoritamab monotherapy Q4W in 28-day Cs for a total of 1 year of treatment. The primary endpoint was investigator-assessed overall response rate (ORR) per Lugano criteria. Key secondary endpoints included CR rate, duration of response (DOR), duration of CR, PFS, OS, and safety/tolerability. Minimal residual disease (MRD) negativity was also assessed as a secondary endpoint u...